A Lesson In Exclusivity? Claritin Falters As Generic Loratadine Sales Double
This article was originally published in The Tan Sheet
Executive Summary
The absence of Hatch/Waxman exclusivity for Schering-Plough's nonprescription Claritin has cost the company millions in potential revenue despite the drug's position as the most successful Rx-to-OTC switch to date